



Antion Biosciences has appointed Dr. Sven Kili as its CEO with immediate effect. He has been involved with the company as a strategic consultant since the spring of 2020, and in his new role will be instrumental in developing the company towards its full potential. Dr. Kili comes on board with extensive, relevant clinical as well as industry experience.

Antion Biosciences develops engineered allogeneic cell therapies utilising a Smart Data approach for patients with under-served and intractable diseases. The company was formed as a spin off from the University of Geneva with technology co-developed with the University of Pretoria and the University of Zurich to build on a ground-breaking multiplex gene-silencing approach to allogeneic cell engineering.

Antion is currently preparing a new financing round to fund the next stage of growth towards new, life-changing therapies for patients.

16 November 2020

Antion Biosciences SA  
Rue Maurice 3  
1204 Geneva  
Switzerland

T: +41 (0)22 310 63 70

M: [info@antion.ch](mailto:info@antion.ch)

[www.antion.ch](http://www.antion.ch)